prevail
therapeutics
announces
appointment
william
carson
board
directors
new
york
globe
newswire
prevail
therapeutics
nasdaq
prvl
biotechnology
company
developing
potentially
gene
therapies
patients
neurodegenerative
diseases
today
announced
appointment
william
carson
board
directors
bill
knows
drive
development
innovative
treatments
including
drugs
wide
range
diseases
affect
brain
concept
commercialization
said
francois
nader
chairman
prevail
board
directors
thrilled
bring
expertise
bear
prevail
continue
develop
gene
therapies
patients
suffering
devastating
neurodegenerative
diseases
including
parkinson
disease
frontotemporal
dementia
gaucher
carson
recently
president
ceo
otsuka
pharmaceutical
development
commercialization
opdc
leading
development
regulatory
approvals
otsuka
global
compounds
including
abilify
also
oversaw
approval
abilify
first
digital
medicine
carson
joined
otsuka
vice
president
princeton
aripiprazole
unit
establishing
company
presence
joining
otsuka
rose
ranks
cns
research
development
department
squibb
prior
joining
pharmaceutical
industry
carson
psychiatrist
associate
professor
department
psychiatry
behavioral
sciences
medical
university
south
carolina
carson
currently
serves
chairman
board
directors
opdc
also
chairman
board
sozosei
foundation
newly
established
otsuka
charitable
organization
main
focus
decriminalization
mental
illness
board
member
excision
biotherapeutics
trustee
board
chair
emeritus
sphinx
organization
advocates
parity
inclusion
arts
carson
holds
degree
harvard
college
degree
case
western
reserve
university
distinguished
fellow
american
psychiatric
association
national
medical
association
executive
leadership
council
carson
named
savoy
magazine
list
top
influential
blacks
corporate
america
dr
carson
outstanding
important
addition
board
directors
said
asa
abeliovich
founder
chief
executive
officer
prevail
know
bring
deep
medical
expertise
compassion
patients
role
well
stellar
track
record
advancing
therapies
clinical
development
fda
approval
honored
join
prevail
exciting
time
company
said
carson
prevail
programs
moving
forward
quickly
promising
data
beginning
emerge
looking
forward
helping
company
continue
advance
mission
developing
potentially
treatments
patients
neurodegenerative
prevail
therapeutics
prevail
gene
therapy
company
leveraging
breakthroughs
human
genetics
goal
developing
commercializing
gene
therapies
patients
neurodegenerative
diseases
company
developing
patients
parkinson
disease
mutations
neuronopathic
gaucher
disease
patients
frontotemporal
dementia
grn
mutations
patients
certain
synucleinopathies
prevail
founded
asa
abeliovich
collaborative
effort
silverstein
foundation
parkinson
gba
orbimed
headquartered
new
york
ny
statements
related
prevail
statements
contained
press
release
regarding
matters
historical
facts
statements
within
meaning
private
securities
litigation
reform
act
amended
examples
statements
include
statements
concerning
prevail
ability
develop
potentially
treatments
patients
neurodegenerative
disorders
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
risks
uncertainties
include
among
others
prevail
novel
approach
gene
therapy
makes
difficult
predict
time
cost
potential
success
product
candidate
development
regulatory
approval
initial
data
preliminary
analyses
results
early
clinical
trials
may
predictive
final
trial
results
results
later
clinical
trials
prevail
gene
therapy
programs
may
meet
safety
efficacy
levels
needed
support
ongoing
clinical
development
regulatory
approval
regulatory
landscape
gene
therapy
rigorous
complex
uncertain
subject
change
fact
gene
therapies
novel
complex
difficult
manufacture
risks
relating
impact
prevail
business
pandemic
similar
public
health
crises
risks
described
fully
prevail
filings
securities
exchange
commission
sec
including
risk
factors
section
company
quarterly
report
form
period
ended
june
filed
sec
august
documents
subsequently
filed
furnished
sec
statements
contained
press
release
speak
date
made
except
extent
required
law
prevail
undertakes
obligation
update
statements
reflect
events
occur
circumstances
exist
date
made
media
contact
mary
carmichael
ten
bridge
communications
mary
